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Abstract
Background: Rifampin is a key drug in antituberculosis chemotherapy because it rapidly kills the
majority of bacilli in tuberculosis lesions, prevents relapse and thus enables 6-month short-course
chemotherapy. Little is known about the pharmacokinetics of rifampin in children. The objective of
this study was to evaluate the pharmacokinetics of rifampin in children with tuberculosis, both
human immunodeficiency virus type-1-infected and human immunodeficiency virus-uninfected.
Methods: Fifty-four children, 21 human immunodeficiency virus-infected and 33 human
immunodeficiency virus-uninfected, mean ages 3.73 and 4.05 years (P = 0.68), respectively, admitted
to a tuberculosis hospital in Cape Town, South Africa with severe forms of tuberculosis were
studied approximately 1 month and 4 months after commencing antituberculosis treatment. Blood
specimens for analysis were drawn in the morning, 45 minutes, 1.5, 3.0, 4.0 and 6.0 hours after
dosing. Rifampin concentrations were determined by liquid chromatography tandem mass
spectrometry. For two sample comparisons of means, the Welch version of the t-test was used;
associations between variables were examined by Pearson correlation and by multiple linear
regression.
Results: The children received a mean rifampin dosage of 9.61 mg/kg (6.47 to 15.58) body weight
at 1 month and 9.63 mg/kg (4.63 to 17.8) at 4 months after commencing treatment administered
as part of a fixed-dose formulation designed for paediatric use. The mean rifampin area under the
curve 0 to 6 hours after dosing was 14.9 and 18.1 μg/hour/ml (P = 0.25) 1 month after starting
treatment in human immunodeficiency virus-infected and human immunodeficiency virus-
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treatment. The mean calculated 2-hour rifampin concentrations in these human immunodeficiency
virus-infected and human immunodeficiency virus-uninfected children were 3.9 and 4.8 μg/ml (P =
0.20) at 1 month after the start of treatment and 4.0 and 4.6 μg/ml (P = 0.33) after 4 months of
treatment. These values are considerably less than the suggested lower limit for 2-hour rifampin
concentrations in adults of 8.0 μg/ml and even 4 μg/ml
Conclusion: Both human immunodeficiency virus-infected and human immunodeficiency virus-
uninfected children with tuberculosis have very low rifampin serum concentrations after receiving
standard rifampin dosages similar to those used in adults. Pharmacokinetic studies of higher dosages
of rifampin are urgently needed in children to assist in placing the dosage of rifampin used in
childhood on a more scientific foundation.
Background
Rifampin (RMP) is a key drug in modern antituberculosis
chemotherapy by virtue of its unique ability to rapidly kill
the majority of bacilli in tuberculosis lesions, prevent
relapse and thus enable 6-month short-course chemother-
apy. Inadequate absorption of RMP has been documented
under different circumstances in a number of studies of
adult tuberculosis patients; it has been found in human
immunodeficiency virus (HIV) type-1-uninfected patients
[1,2], amongst HIV-infected patients [3-5], and in some
studies amongst both HIV-infected and HIV-uninfected
patients [6-8]. In another recent study, although low RMP
plasma concentrations were found in both HIV-infected
and HIV-uninfected patients, HIV-infected patients were
at greater risk for poor RMP absorption [9]. Others evalu-
ating smaller numbers of patients have found adequate
absorption amongst HIV-infected patients [10,11]. It has
also been remarked that there is considerable intra-indi-
vidual variation in RMP pharmacokinetics.
There is very little available information describing RMP
pharmacokinetics in children and there is no information
regarding the possible influence of HIV infection on RMP
pharmacokinetics in children. This paper describes the
pharmacokinetics of RMP in a group of children from the
Western Cape Province of South Africa, both HIV-infected
and HIV-uninfected, admitted to a tuberculosis referral
hospital with severe forms of childhood tuberculosis.
Methods
Setting
The Brooklyn Hospital for Chest Diseases (BHCD) is a
referral hospital for severe forms of tuberculosis occurring
within the city of Cape Town. During the period January
2004 to December 2006 children aged 3 months to 13
years admitted to BHCD were eligible for enrolment in a
study of the pharmacokinetics of antituberculosis agents.
Admission to BHCD occurred approximately 1 month
after commencement of treatment at the referring hospi-
tal.
Diagnosis of tuberculosis
The diagnosis of tuberculosis was confirmed by culture of
gastric aspirate, or sputum in older children, together with
culture of cerebrospinal fluid in suspected cases of tuber-
culous meningitis; these investigations were usually car-
ried out at referring hospitals before admission to BHCD.
Mantoux testing was with tuberculin RT23 and induration
was measured in the transverse diameter of the forearm
after 48 to 72 hours. Induration of at least 10 mm was
taken as indicative of Mycobacterium tuberculosis infection
in HIV-uninfected children, but at least 5 mm in those
HIV-infected. All parents or caregivers were questioned as
to the presence in the child's household within the last
year of cases of sputum-microscopy, smear-positive pul-
monary tuberculosis. Chest radiographs were considered
indicative of pulmonary tuberculosis in the presence of
unequivocal mediastinal adenopathy; a diagnosis of
tuberculous meningitis was accepted in the presence of
hydrocephalus and basal enhancement seen on cranial
computerised tomography, accompanied by appropriate
cerebrospinal fluid changes. Two or more of the above
clinical criteria were required to establish a diagnosis of
probable tuberculosis.
Treatment
Treatment for all forms of tuberculosis was with fixed-
dose combinations (FDC) formulated for paediatric use;
each tablet used during the intensive treatment phase con-
tained RMP 60 mg, isoniazid (INH) 30 mg and pyrazina-
mide 150 mg (RimcureR) and during the continuation
phase RMP 60 mg and INH 30 mg (RimactazidR). One
tablet was used for every 5 kg increase in body weight.
RimcureR and RimactazidR were supplied by Sandoz SA
Pty Ltd Spartan, South Africa; these formulations are
approved by the South African Medicines Control Council
and were dispensed by the BHCD pharmacy. During the
intensive phase ethambutol was added when the use of
four drugs was considered advisable. Tuberculous menin-
gitis was managed with the same FDC, but with ethiona-
mide added, all given for 6 months. All tuberculosisPage 2 of 10
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ing staff. On the day of a pharmacokinetic study, drug
administration was undertaken by study personnel. All of
the children were supplemented with a multivitamin
syrup. This supplied pyridoxine 0.5 mg for children aged
0 to 4 years, but 1 mg for those >5 years; each 5 ml con-
tained vitamin A 2300 IU, vitamin D 200 IU, vitamin B1
1 mg, vitamin B2 1.2 mg, nicotinamide 5 mg, vitamin C
35 mg and vitamin B12 0.0025 mg. All HIV-infected chil-
dren received trimethoprim-sulphamethoxazole. Antiret-
roviral treatment consisted of two nucleoside reverse
transcriptase inhibitors and ritonavir in children less than
3 years of age (KaletraR was not yet available), and ritona-
vir was replaced by efavirenz in children older than 3
years.
Pharmacokinetic study
RMP plasma concentrations were measured within a week
of admission to BHCD (approximately 1 month after ini-
tial admission to the referral hospital) and again 4
months after commencing treatment to evaluate the pos-
sible influence of nutrition, disease state and intra-indi-
vidual variation on RMP pharmacokinetics. The children
were nil per mouth from midnight and an intravenous
catheter was inserted after the application of a local anaes-
thetic jelly (AmetopR). Medication was administered by
study personnel. Blood specimens were taken at 45 min-
utes, 1.5, 3.0, 4.0 and 6.0 hours after dosing, immediately
placed on ice and centrifuged within 30 minutes. A
plasma sample of 1 ml was stored in polypropylene tubes
at -80°C and protected from light until analysed. The
specimens were analysed for RMP by liquid chromatogra-
phy tandem mass spectrometry as described previously
[12]; the limit of quantification was 0.1 μg/ml. The refer-
ence standard for RMP was purchased from Sigma
(StLouis, MO, USA).
Nutritional and clinical evaluation
Body mass and height, or length in those less than 2 years
of age, and mid-upper arm circumference were measured
by standard anthropometric methods by a qualified dieti-
cian and the mean of three readings taken [13,14]. Serum
bilirubin and alanine transferase (ALT) were determined
at the time of each pharmacokinetic evaluation.
The presence of abdominal nodes was evaluated by
abdominal ultrasound at enrolment in all children.
Plasma C-reactive protein (CRP) was determined by an
immunoradiometric assay at 1 and 4 months of treatment
in all children [15].
The children's HIV status was determined by enzyme-
linked immunosorbent assay and positive results con-
firmed by a second assay, or by polymerase chain reaction
in children younger than 18 months. Counselling of the
parents or legal guardians preceded HIV-testing and writ-
ten informed consent was obtained.
Statistics
For two sample comparisons of means the Welch version
of the t-test was used; associations between variables were
examined by Pearson correlation and by multiple linear
regression. Cmax is the observed maximum value for each
individual and Tmax the time at which Cmax was recorded.
The area under the curve (AUC) over the period 0 to 6
hours after dosing was calculated by the linear trapezoidal
rule. Experience with published reference ranges for RMP
plasma concentrations from studies in healthy volunteers
and tuberculosis patients have suggested that 2-hour con-
centrations of less than 8 μg/ml should be regarded as low
and values less than 4 μg/ml as very low [5,8,16]. The 2
hours after dosing RMP plasma concentrations were thus
calculated as [(2/3)(1.5 hour value+(1/3)(3.0 hour
value)]. These calculated values were compared with
interpolated values obtained from fitting a two-compart-
ment regression model to the data. The correlation coeffi-
cients between the two sets of interpolated values were
0.983 and 0.982 at enrolment and at 4 months after treat-
ment commencement, respectively, with negligible bias
between the mean values.
The study was approved by the Institutional Review Board
of the Faculty of Health Sciences of Stellenbosch Univer-
sity (No. 2003/054/N). All parents or legal guardians gave
written informed consent for their children's participation
in the study.
Results
Sixty children, 26 HIV-infected and 34 HIV-uninfected,
were enrolled in the study. Four children (all HIV-
infected) were transferred back to referring hospitals
shortly after enrolment due to complications that could
not be managed at BHCD and were not studied further;
two children (one each HIV-infected and HIV-uninfected)
were discharged from hospital after completion of the first
pharmacokinetic study and their data were not included
in this analysis. Due to our inability to maintain the intra-
venous line, single data points were not available for 14
children (usually the 6-hour data point), two data points
were missing from two children and three data points
from one patient. Pharmacokinetic data were thus availa-
ble for analysis on enrolment and after 4 months of treat-
ment from 21 HIV-infected children and 33 HIV-
uninfected children. The period between the start of treat-
ment and admission to BHCD and enrolment in the study
at BHCD did not differ between the HIV-infected and
HIV-uninfected children: 34.2 days (standard deviation
(SD) 21. 8) and 38.0 days (SD 19.3), respectively (P =
0.49).Page 3 of 10
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roviral treatment at the time of admission to BHCD and a
further seven children were commenced on antiretroviral
treatment, but this occurred only shortly before the com-
pletion of the second pharmacokinetic study.
Demographic, diagnostic and clinical features of the chil-
dren are summarised in Table 1. Overall a culture of M.
tuberculosis was obtained from 28 (51%) children and in a
further three HIV-infected children with negative cultures,
acid-fast bacilli were seen on microscopy of gastric aspi-
rates. Only four (20%) HIV-infected children had a posi-
tive Mantoux test and this was greater than 10 mm in each
case. A majority of children suffered from one or other
form of malnutrition; although the proportion of HIV-
uninfected children suffering from kwashiorkor and with
a body mass less than the third percentile for age was sim-
ilar to that amongst HIV-infected children, significantly
more HIV-infected children were marasmic.
Table 2 summarises certain anthropometric features and
CRP concentrations of the children on enrolment (after 1
month of treatment) and after 4 months treatment. At nei-
ther assessment did the anthropometric findings differ
between the HIV-infected or HIV-uninfected children. At
the 4-month assessment the anthropometric parameters
showed improvement in both groups of children. On
enrolment the mean CRP concentrations were raised in
both groups of children, but were significantly higher in
the HIV-infected children; by the 4-month assessment the
CRP concentrations had declined in both groups, but
while those of the HIV-uninfected children had normal-
ised, with the exception of two children, those of the HIV-
infected children remained elevated. With regard to liver
function evaluation, no child had a raised serum
Table 1: Demographic, diagnostic, clinical and radiological features of human immunodeficiency virus (HIV)-infected and HIV-
uninfected children being treated for tuberculosis.
Human immunodeficiency virus-
infected
N = 21
Human immunodeficiency virus-
uninfected
N = 33
P value
Age (years) 3.73 4.05 0.68
Male sex 12 (57%) 16 (48%) 0.58
Culture of M. tuberculosis or acid-fast bacillus smear 
seen on microscopy1
10 (48%) 18 (60%) 0.16
Household tuberculosis contact 14 (67%) 23 (70%) 0.82
Mantoux test2
≥ 10 mm 4 (20%) 30 (91%) <0.001
≥ 5 mm - -
Clinical features
Pulmonary tuberculosis 18 (86%) 27 (82%) 0.72
Tuberculous meningitis 7 (33%) 19 (58%) 0.16
Nutritional status
Mass <3rd percentile for age 8 (38%) 13 (39%) >0.99
Kwashiorkor 6 (29%) 6 (18%) 0.50
Marasmus 8 (38%) 3 (9%) 0.014
Marasmic kwashiorkor 4 (19%) 3 (9%) 0.41
Radiological features
Hilar adenopathy 11 (52%) 18 (55%) >0.99
Lobar opacification 9 (43%) 10 (30%) 0.39
Micronodular opacification 5 (24%) 7 (21%) >0.99
Cavitation 0 6 (18%) 0.072
Abdominal nodes3 5 (24%) 6 (18%) 0.73
1Culture and microscopy not carried out in three human immunodeficiency virus (HIV)-uninfected children.
2Mantoux test not read in one HIV-uninfected child.
3Abdominal nodes visualised on ultrasound.Page 4 of 10
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serum ALT was raised (more than 37 U/litre) in three
(14.3%) HIV-infected children and was more than three
times the normal level in two children (9.5%), while
amongst the HIV-uninfected children, four (12.1%) chil-
dren had an increased ALT and this was more than three
times the normal level in two (6.1%) At 4 months ALT
was increased in 6 (28.6%) HIV-infected children, but
more than three times the normal in only two (9.5%) and
amongst the HIV-uninfected ALT was raised in four chil-
dren (12.1%) and in none was the value more than three
times the normal level.
The children received a mean RMP dosage of 9.61 mg/kg
(range 6.47 to 15.58, SD 1.69) for the pharmacokinetic
study on enrolment and 9.63 mg/kg (range 4.63 to 17.8,
SD 2.26) during the 4-month study (P = 0.93). On enrol-
ment one HIV-uninfected child received a RMP dose of
less than 8 mg/kg and two HIV-uninfected children and
one HIV-infected child a dose of more than 12 mg/kg;
during the 4-month assessment two HIV-uninfected chil-
Table 2: Anthropometrical evaluation and serum C-reactive protein levels in human immunodeficiency virus (HIV)-infected and HIV-
uninfected children being treated for tuberculosis on enrolment after 1 month and 4 months of treatment.
Human 
immunodeficiency 
virus-infected
N = 21 (SD)
Human 
immunodeficiency 
virus-
uninfected
N = 33
(SD)
P value Human 
immunodeficiency 
virus-infected
N = 21
(SD)
Human 
immunodeficiency 
virus-uninfected
N = 33
(SD)
P value
On enrolment After 4 months of
treatment
Weight (kg) 12.26
(5.18)
13.97
(6.94)
0.30 13.06
(5.33)
15.04
(8.01)
0.29
Length/height (cm) 86.80
(16.22)
91.53
(20.85)
0.36 89.26
(16.39)
93.67
(20.37)
0.40
Body mass index 15.59
(1.62)
15.71
(1.91)
0.80 15.74
(1.53)
16.05
(1.71)
0.51
Mid-upper arm 
circumference (cm)
14.28
(2.16)
15.07
(2.39)
0.21 14.44
(2.22)
15.46
(2.63)
0.16
Serum C-reactive 
protein
(mg/litre)
39.97
(54.55)
13.42
(17.96)
0.06 22.47
(22.28)
4.15
(4.96)
0.002
SD, standard deviation.
Table 3: Mean rifampin plasma concentrations (μg/ml) in human immunodeficiency virus (HIV)-infected and HIV-uninfected children 
being treated for tuberculosis on enrolment after 1-month and 4-months of treatment.
Time after 
dosing (hours)
Enrolment (SD) 4 months (SD)
N Human 
immunodeficiency 
virus-infected
N Human 
immunodeficiency 
virus-uninfected
P
value
N Human 
immunodeficiency 
virus-infected
N HIV-uninfected P value
0.75 21 2.35(2.54) 32 4.02(5.10) 0.12 20 3.11(3.45) 33 3.84(3.72) 0.47
1.5 21 4.26(1.96) 33 5.63(4.07) 0.10 21 4.28(2.66) 33 5.31(3.01) 0.19
2.01 21 3.90(1.67) 33 5.07(3.59) 0.11 21 4.00(2.04) 32 4.61(2.43) 0.33
3.0 20 3.01(1.96) 33 3.93(3.50) 0.22 21 3.43(2.83) 32 3.58(2.42) 0.84
4.0 21 2.22(1.67) 32 3.17(4.54) 0.29 20 2.60(1.74) 32 2.41(1.94) 0.72
6.0 16 1.12(1.41) 28 1.95(4.45) 0.37 17 1.09(0.88) 30 0.88(0.96) 0.47
Cmax (μg/ml) 21 4.91(2.03) 33 6.92(5.88) 0.08 21 5.67(3.30) 33 6.26(3.41) 0.53
Tmax (hour) 21 1.80(0.87) 33 1.67(0.93) 0.62 21 2.17(1.30) 33 1.71(0.88) 0.17
AUC0–6 (μg/hour/
ml)
21 14.88(7.43) 32 18.07(12.52) 0.25 21 16.52(8.84) 33 17.94(10.36) 0.59
1The 2-hour plasma concentrations are calculated as [(2/3)(1.5 hour value+(1/3)(3.0 hour value)].
Cmax = observed maximum value for each individual; Tmax = the time at which Cmax was recorded.
AUC, area under the curve.Page 5 of 10
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uninfected children a dose of more than 12 mg/kg.
Table 3 gives the RMP plasma concentrations determined
at 45 minutes, 1.5 hours, 3.0 hours, 4.0 hours and 6.0
hours and those calculated for 2 hours after dosing 1
month and 4 months after commencing treatment; Figure
1 illustrates these serum concentrations in HIV-infected
and HIV-uninfected children. The mean AUC0–6 on enrol-
ment was 14.88 and 18.07 μg/hour/ml (P = 0.25) in HIV-
infected and HIV-uninfected children, respectively, and
after 4 months of treatment 16.52 and 17.94 μg/hour/ml
(P = 0.59). While a majority of children have a consistent
AUC0–6 on both occasions there was considerable inter-
individual and intra-individual variation evident. Thus,
the AUC0–6 of all 55 children was 16.81 (SD 10.82) on
enrolment and 17.39 (SD 9.74) after 4 months of treat-
ment, but the correlation of the AUC0–6 on enrolment
with that after 4 months of treatment was low (r = 0.313,
P = 0.022). There was no correlation between AUC0–6 and
body mass index either at enrolment (one outlier
excluded) or at 4 months of treatment (r = 0.109, P =
0.444; r = 0.014, P = 0.920, respectively).
The mean calculated 2-hour RMP concentrations of the
HIV-infected and HIV-uninfected children on enrolment
were 3.90 and 4.78 μg/ml, respectively; although these
mean values did not differ significantly (P = 0.20), the SD
of the HIV-infected group (3.25) was significantly greater
(P = 0.002) than that of the HIV-uninfected group (1.67).
At the 4-month assessment the mean calculated 2-hour
RMP plasma concentrations of the HIV-infected and HIV-
uninfected groups were 3.96 μg/ml (SD 2.04) and 4.61
μg/ml (SD 2.43), respectively, and neither the means (P =
0.33) nor the SD (P = 0.40) differed significantly. At the
first pharmacokinetic evaluation on enrolment only five
(9%) children had calculated 2-hour concentrations
greater than 8 μg/ml, while 25 (47%) had values less than
4 μg/ml; although more HIV-infected than HIV-unin-
fected children had such low values (57% and 41%,
respectively), the difference was not significant (P = 0.37).
At 4 months after treatment commencement three chil-
dren (6%) had 2-hour RMP concentrations greater than 8
μg/ml and 25 (43%) values less than 4 μg/ml; the propor-
tions of HIV-infected and uninfected children with such
very low values were 39% and 43%, respectively (P =
0.83). There was no relationship between HIV staging and
RMP plasma concentrations either on enrolment or after
4 months of treatment.
In children with and without abdominal nodes visible on
ultrasound examination on enrolment the mean Cmax
concentrations were 5.3 μg/ml (SD 5.2) and 6.3 μg/ml
(SD 3.4), respectively, and at 4 months after commence-
ment of treatment 5.3 μg/ml (SD 2.9) and 6.2 μg/ml
(3.5), and neither of these differences were significant.
The study was not intended to compare the outcome of
treatment, but on discharge from BHCD all children who
had a positive culture of M. tuberculosis on commence-
ment of treatment were culture-negative. We are aware of
one HIV-infected child who has subsequently relapsed,
but the children were not specifically followed up to
detect relapse. Of the 21 HIV-infected children three
(14.3%) had not gained in weight compared to three
(8.8%) of the 34 HIV-uninfected children. Sixteen HIV-
infected children had an abnormal chest radiograph on
study commencement and by the time of discharge six
children (37.5%) showed some clearing, five (31.3%) had
cleared, but five (31.3%) remained unchanged. Amongst
the 34 HIV-uninfected children, 27 initially had chest
radiographic abnormalities and of these 15 (55.6%) had
improved and 12 (44.4%) had cleared. No association
was shown between these features and any aspect of RMP
pharmacokinetics.
Discussion
This study has documented very low serum RMP concen-
trations in children, of which the great majority received
the often recommended standard dosage of 8 to 12 mg/kg
body weight. Although there was a trend for lower con-
centrations in HIV-infected children on the first evalua-
tion 1 month after commencing treatment this was not
significant and the 4-month evaluation provided no evi-
dence of differences between the HIV-infected and HIV-
uninfected children. Early studies of RMP pharmacokinet-
ics in children under 18 months of age, conducted
amongst children not established on RMP, reported an
elimination rate similar to that in adults, but a volume of
distribution twice that of adults; RMP absorption was
noted to be 'erratic and unpredictable' [17]. In compari-
son to adults young children receiving a RMP dosage of 10
mg/kg appeared to reach considerably lower concentra-
tions of RMP [18]. The relatively low plasma concentra-
tions of RMP reached by children were also evident in
other studies and amongst children not established on
RMP and receiving a dosage of 10 to 12 mg/kg peak con-
centrations of 3 to 9 μg/ml were found [18-22]; it should
be noted that the highest values derive from a study dur-
ing which RMP was administered in a suspension [21],
peak concentrations amongst children established on
RMP ranged from approximately 3 to 5 μg/ml (see [23-
25]). On the basis of their findings Hussels et al. [20] con-
sidered that children under 6 years of age should receive a
RMP dose of 15 mg/kg body weight and older children 10
mg/kg.
Comparison of our results with those from adult studies
is difficult due to considerable variation in how pharma-Page 6 of 10
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AUC may be presented calculated over 0 to 6, 0 to 12 or 0
to 8 hours. Considerable experience in healthy volunteers
and tuberculosis patients has led to the suggestion that
RMP concentrations of less than 8 μg/ml 2 hours after
dosing should be regarded as low and values less than 4
μg/ml as very low and frequent reference is made in the
literature to these values [5,8,16]. To enable us to compare
our results with these values we calculated the 2-hour
RMP serum concentrations in our patients; even allowing
for the introduction of a degree of inaccuracy it is clear
that, both HIV-infected and HIV-uninfected children, the
great majority of whom received the often recommended
standard RMP dosages of 8 to 12 mg/kg body weight
[26,27], have very low RMP serum concentrations. Close
to half the calculated 2-hour concentrations were less than
4.0 μg/ml. This is true of the calculated 2-hour values at
both enrolment and after 4 months of treatment. By 4
months the nutritional condition of many of the HIV-
uninfected children had improved significantly, but their
RMP plasma concentrations remained low, so that poor
nutrition cannot fully explain this finding. Equally,
although both groups of children had evidence of an
acute inflammatory response on enrolment, as indicated
by elevated serum CRP concentrations, by 4 months after
treatment initiation, although there was continued evi-
dence of an acute inflammatory response in the HIV-
infected children, all except two of the HIV-uninfected
children had normal CRP values.
Two previous studies amongst adult African tuberculosis
patients from Kenya and Botswana reported low RMP
concentrations similar to those found in our children and
also no difference between HIV-infected and HIV-unin-
fected patients [6,8]. However, another study from Cape
Town reported low RMP plasma concentrations from 88
adult tuberculosis patients with a median 2-hour plasma
concentration of 4.4 μg/ml, and found HIV infection to be
associated with a 39% reduction in RMP concentrations
with 22% of 2-hour values less than 4 μg/ml (see [9]).
In other fields of medicine, such as oncology, it is com-
mon practice to determine the dose of an agent for chil-
dren by reference to body surface area or by making use of
percentage of the adult dose as determined, directly or
indirectly, from body surface area [28]. Alternatively
weight-based bands can be constructed that provide a sat-
isfactory approximation to the use of body surface area
and such an approach has been suggested for certain
antiretroviral drugs to be administered under programme
conditions [29]. Nonetheless recommendations for the
dose of RMP for children by the World Health Organiza-
tion [26,27] and several other bodies make use of the
same milligram per kilogram body weight dosage as is rec-
ommended for adults. Using a percentage of the adult
dose reckoned according to an approximation of body
surface area [28] in an hypothetical 10 kg child leads to a
RMP dose of 162 mg; if this is then reconverted to a milli-
gram per kilogram dose this would be 16 mg/kg com-
pared with a RMP dosage of 100 mg calculated according
to a flat-rate of 10 mg/kg; it is of interest that the dosage
of RMP recommended for use in children in the USA is 15
mg/kg with a range of 10 to 20 mg/kg body weight [30].
Do the differences in exposure to lower serum concentra-
tions of RMP (and other antituberculosis agents) that
arise from using the same milligram per kilogram body
weight dose in children as in adults matter? On the one
hand there are a number of studies documenting a satis-
factory response of children with tuberculosis to regimens
of drugs used in the currently recommended dosages and
several recent studies have suggested a lack of any rela-
tionship between RMP serum concentrations and sputum
culture-conversion in adults [31,32]. On the other hand,
it is also becoming apparent that, in the era of HIV/
acquired immune deficiency syndrome, any reduction in
the dose of antituberculosis agents reflected by frequency
and length of treatment, particularly in more severe forms
of pulmonary tuberculosis may be associated with an
increased risk of relapse [33-36]. In immunocompetent
patients a RMP 600 mg dosage, associated with INH, led
to more rapid sputum sterilisation of adult pulmonary
tuberculosis patients than a dosage of 450 mg (see [37]);
Buniva et al. [38], after extensive experience with the
development of RMP, stated that Tmax was usually reached
at between 1.5 and 2 hours in human volunteers and that
the mean Cmax in 95 individuals after dosages of 600 mg
was 12.7 μg/ml (± 0.4), with individual values ranging
from 7.6 to 25.9 μg/ml (see [38]). This suggests that the
proposed lower limit of normal 2-hour, post-dose con-
centrations of RMP is appropriate [16]. In studies of early
bactericidal activity a RMP dosage of 600 mg was more
efficient at killing the metabolically active organisms
present in sputum than a dosage of 300 mg, while a dos-
age of 150 mg had no detectable effect [39,40]. The mean
RMP peak serum concentration associated with a dosage
of 600 mg in early bactericidal activity studies amongst
Chinese patients [39] was 9.53 μg/ml on the second day
of treatment and amongst African patients 13 μg/ml and
9.5 μg/ml on the first and fifth days of treatment, respec-
tively [40]. At the less efficacious dosage of 300 mg the
mean peak RMP concentration amongst Chinese patients
on the second treatment day was 3.27 μg/ml, and
amongst African patients, 3.19 and 2.9 μg/ml and on the
first and fifth treatment days, respectively.
Conclusion
This study has documented very low serum RMP concen-
trations in children, the great majority of whom received
the often recommended standard dosage of 8 to 12 mg/kgPage 8 of 10
(page number not for citation purposes)
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management of less serious forms of childhood tubercu-
losis, it might well be very relevant in more severe forms
of tuberculosis such as are increasingly encountered in the
developing world, especially in association with HIV-
infection. From our data we believe that the recom-
mended RMP dose of 10 to 20 mg/kg for children by the
American Academy of Pediatrics is a more appropriate
dosage range [41]. Studies of higher dosages of RMP in
younger children are urgently needed to place the dosing
of antituberculosis drugs in children on a more rational
foundation.
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